Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ceftazidime→

Ceftazidime Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
72558-82-8
Molecular formula
C22H22N6O7S2
Molecular weight
546.6 g/mol
Drug class
Third-generation cephalosporin beta-lactam antibacterialantipseudomonal agent
Mechanism of action
Inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins and disrupting peptidoglycan cross-linking. It has activity against susceptible Gram-negative organisms including Pseudomonas aeruginosa; susceptibility varies by strain and resistance mechanisms.
Indications / reported uses
  • Treatment of serious infections caused by ceftazidime-susceptible organisms, including selected lower respiratory-tract, urinary-tract, skin/soft-tissue, intra-abdominal, bone/joint, septicaemia and CNS infections; use should be guided by culture results and local antimicrobial guidance

Sources: US DailyMed — Ceftazidime injection · NLM MeSH — Ceftazidime · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ceftazidime Environmental Risk Assessment (ERA) (the Ceftazidime ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.